1Holger N, Rong X, Becker JC, et al. Immunocytokines: a promising approach to cancer immunotherapy[J]. Pharmacol Ther, 1998, 80(3): 277-292.
2Jim Xiang. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins[J]. Hum Antibodies, 1999, 9: 23-36.
3Helguera G, Morrison SL, Penichet ML. Antibody-cytokine fusion protein: harnessing the combined power of cytokines and antibodies for cancer therapy[J]. Clinical Immunology, 2002, 105(3): 233-246.
4Shi M, Xie ZG, Feng JN, et al. A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function[J]. Biotechnol Letters, 2003, 25: 815-819.
5Hu P, Mizokami M, Ruoff G, et al. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity[J]. Blood, 2003, 101(12): 4853-4861.
6Heuser C, Ganser M, Hombach A, et al. An anti-MUCI-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUCI-positive tumour cells[J]. Bri J Cancer, 2003, 89: 1130-1139.
7Penichet ML, Dela Cruz JS, Shin SU, et al. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu-expressing tumors[J]. Hum Antibodies, 2001, 10: 43-49.
8Penichet ML, Challita PM, Shin SU, et al. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice[J]. Lab Anim Sci, 1999, 49: 179-188.
9Budagian V, Nanni P, Lollini PL, et al. Enhanced inhibition of tumour growth and metastasis, and induction of antitumor immunity by IL-2-IgG2b fusion protein[J]. Scand J Immunol, 2002, 55: 484-492.
10Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumour activity of interleukin-12 by targeted delivery to neovasculature[J]. Nature Biontechol, 2002, 20: 264-269.
